Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Edesa Biotech, Inc.

Get SEC filing alerts via email and in your feed for Edesa Biotech, Inc.

EDSA

Edesa Biotech, Inc.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. Its pipeline includes monoclonal antibodies targeting conditions like vitiligo, ARDS, pulmonary fibrosis, and contact dermatitis. The company leverages validated technology, intellectual property, and strategic licensing to address large unmet medical needs, aiming for regulatory approval and commercialization through partnerships or direct sales.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Edesa Biotech, Inc.

1
1
Edesa Biotech, Inc. Edesa Biotech Reports Increased Losses and R&D Spending in Q2 Fiscal 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Edesa Biotech, Inc. Edesa Biotech Reports $2.2 Million Net Loss and Increases Cash Reserves to $12.1 Million

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Edesa Biotech, Inc. Edesa Biotech Reports $7.2 Million Net Loss and Advances Clinical Pipeline

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
Edesa Biotech, Inc. Edesa Biotech Reports $1.7 Million Net Loss and Significant Cash Increase in Latest Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Edesa Biotech, Inc. Edesa Biotech Reports $3.2 Million Net Loss and Increased Cash Reserves for Six Months Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Edesa Biotech, Inc. Edesa Biotech Reports $1.6 Million Net Loss, Increases Total Assets to $4.2 Million

Via official filing (AI summary) | over 1 year ago | 0 comments